| Before
listening to the TALK,take the same quiz that was given to the San Francisco audience
and compare your results with theirs. |  |
Upon completion of this
activity, participants should be able to: - Discuss
the prevalence of chronic kidney disease (CKD) and anemia of CKD
- Discuss
the problem of underdiagnosis and undertreatment of anemia
- Explain
the relationship between effective management of chronic kidney disease and clinical
outcomes
- Describe
new data related to pre-dialysis patients
- Identify
the economic impact of anemia management
- Describe
the link between CKD, anemia, and heart disease
|
 |
Allan Collins,
M.D.
Minneapolis Medical Research Foundation
Minneapolis, Minnesota
Adeera Levin, M.D.
Associate Clinical Professor
Director,
Postgrad Education, Nephrology
University of British Columbia
St. Paul's
Hospital
Vancouver, British Columbia
Francesco Locatelli, M.D.
Scientific Director and Chief of Nephrology Department,
A. Manzoni Hospital
Lecco, Italy
Brian J. G. Pereira, M.D., M.B.A.
Senior Vice-President
New England Medical Center
Louisa C. Endicott Professor of Medicine
Tufts
Univ. School of Medicine Boston, Massachusetts. | |
 |
| The
Postgraduate Institute for Medicine designates this activity for a maximum
of 2 hours in category 1 credit toward the AMA Physician's Recognition Award. |
| | Estimated
time to complete activity: 2.0 hours
Posting date: December
15, 2001
Review date: December 15, 2002
Expiration date: December 15,
2003 # | 
To
obtain a statement of participation, you must complete the post-test by recording
the best answer to each question in the answer key on the evaluation form, complete
the evaluation form, and mail or fax the evaluation form with answer key to the
Postgraduate Institute for Medicine.
|  |
Post-test
and evaluation form is at this
link, but you must listen to all four
talks from this symposium prior to completing
the test
|
This activity
has been designed to meet the educational needs of nephrologists involved in the
treatment of patients with CKD and anemia.
Chronic
kidney disease affects 30-40 million Americans and is hence a major health care
problem. Anemia of CKD is a preventable and treatable complication of CKD and
is yet under recognized and under treated. Nephrologists should be sensitized
to the above two facts and are the target audience for this message. This emerging
information would be necessary to improve anemia management and consequently classical
outcomes.
|
ACCREDITATION STATEMENT : |
This activity has been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education
(ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine
and HealthVizion Communications. The Postgraduate Institute for Medicine is accredited
by the ACCME to provide continuing medical education for physicians and takes
responsibility for the content, quality, and scientific integrity of this CME
activity.
|
DESIGNATION STATEMENT(S) : | The
Postgraduate Institute for Medicine designates this educational activity for a
maximum of 2 hours in category 1 credit toward the AMA Physician's Recognition
Award. Each physician should claim only those hours of credit that he/she actually
spent in the activity.
|
FACULTY DISCLOSURE STATEMENTS : | Postgraduate
Institute for Medicine has a conflict of interest policy that requires course
faculty to disclose any real or apparent commercial financial affiliations related
to the content of their presentations/materials. It is not assumed that these
financial interests or affiliations will have an adverse impact on faculty presentations;
they are simply noted here to fully inform participants.
Dr. Collins: Grants/Research Support: Amgen, Inc.
Dr. Levin: Grants/Research Support and Consultant: Amgen, Inc., Genzyme Inc.,
Ortho Biotech, Roche Pharmaceuticals, Jansen
Dr. Locatelli: Dr. Locatelli had no financial relationships with commercial entities
related to his presentation
Dr. Pereira: Grants/Research Support: Amgen, Inc.
Consultant: Amgen, Inc.,
Baxter; Speakers' Bureau: Amgen, Inc.
|
DISCLOSURE OF UNLABELED USE : | Faculty
of this CME activity may include discussions of products or devices that are not
currently labeled for use by the FDA. Faculty members will disclose to the audience
any reference to an unlabeled or investigational use. The Postgraduate Institute
for Medicine, HealthVizion Communications, and Amgen, Inc. do not recommend the
use of any agent outside of the labeled indications. Please refer to the official
prescribing information for each product for discussion of approved indications,
contraindications and warnings.
Participants
have an implied responsibility to use the newly acquired information to enhance
patient outcomes and their own professional development. The information presented
in this activity is not meant to serve as a guideline for patient management.
Any procedures, medications, or other courses of diagnosis or treatment discussed
or suggested in this activity should not be used by clinicians without evaluation
of their patient's conditions and possible contraindications on dangers in use,
review of any applicable manufacturer's product information, and comparison with
recommendations of other authorities. |
|
